In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

The Reconstruction of Zimmer

Executive Summary

Long the market leader in orthopedics, Zimmer has seen itself leap-frogged by companies formed out of the recent wave of consolidation in the orthopedic industry. Free of its long-time pharmaceutical parent, Bristol-Myers Squibb, through the largest spin-off in health care history, Zimmer is looking to capitalize on its independence to get into high growth market segments the company was previously precluded from entering, such as spine and biologicals. Despite not being a player in the fastest-growing segments of orthopedics, spine and sports medicine, Zimmer has been consistently producing outstanding financial results, benefiting in part from investors' current strong support of orthopedics as a whole. In this interview, Zimmer's chairman and CEO, J. Raymond Elliott discusses how the company plans to utilize innovative approaches including direct-to-consumer advertising and minimally-invasive techniques and devices to drive Zimmer back to prominence.
Advertisement

Related Content

Navigating Ortho's Choppy Seas: An Interview with Zimmer's David Dvorak
Navigating Ortho's Choppy Seas: An Interview with Zimmer's David Dvorak
Orthopedics Through a Keyhole
Orthopedics Through a Keyhole
Zimmer Enlists Medtronic to Advance Less Invasive Joint Replacement
Zimmer Enlists Medtronic to Advance Less Invasive Joint Replacement
Zimmer Redux
Zimmer Returns To Its Roots

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

IV001585

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel